Lead Story
FDA approves first mRNA-based flu vaccine for older adults
On August 5, 2026, the FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, marking the first flu shot in the United States built on messenger RNA technology, the same platform that powered the COVID-19 vaccines. The agency granted standard approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with Moderna required to run an additional confirmatory trial in the older group. In a late-stage clinical trial, mFLUSIVA proved about 27% more effective than a standard flu shot, and no new or serious safety concerns were identified by Moderna or FDA reviewers. Moderna says the vaccine will reach pharmacies within a few weeks, in time for the 2026-2027 respiratory virus season. The approval also opens the door to future combination shots pairing flu protection with COVID-19 or RSV vaccines in a single mRNA injection. Public health officials see the approval as a milestone showing mRNA technology can be adapted well beyond the pandemic to one of medicine's most common seasonal illnesses.
Read more →Lead Story
FDA approves first mRNA-based flu vaccine for older adults
On August 5, 2026, the FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, marking the first flu shot in the United States built on messenger RNA technology, the same platform that powered the COVID-19 vaccines. The agency granted standard approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with Moderna required to run an additional confirmatory trial in the older group. In a late-stage clinical trial, mFLUSIVA proved about 27% more effective than a standard flu shot, and no new or serious safety concerns were identified by Moderna or FDA reviewers. Moderna says the vaccine will reach pharmacies within a few weeks, in time for the 2026-2027 respiratory virus season. The approval also opens the door to future combination shots pairing flu protection with COVID-19 or RSV vaccines in a single mRNA injection. Public health officials see the approval as a milestone showing mRNA technology can be adapted well beyond the pandemic to one of medicine's most common seasonal illnesses.
FDA approves first drug to treat the full range of narcolepsy symptoms
On August 5, 2026, the FDA approved Orzeyful (oveporexton), the first medicine designed to treat narcolepsy type 1 as a single, unified disorder rather than a collection of separate symptoms. Developed by Takeda, the twice-daily oral tablet is also the first approved drug that works by directly restoring orexin signaling, the brain chemical whose loss causes the disease, rather than masking symptoms with stimulants or sedatives. Approval rested on two randomized, double-blind, placebo-controlled trials enrolling 273 adults; patients on Orzeyful showed significantly longer ability to stay awake during the day and markedly fewer cataplexy episodes, with incidence-rate ratios of 0.34 to 0.38 versus placebo. Patients also reported improvement across the disorder's full symptom range, including sleep paralysis, hallucinations, and disrupted nighttime sleep. The drug received Breakthrough Therapy Designation and Priority Review earlier in 2026, reflecting the urgency researchers felt for a therapy addressing the disease's root cause rather than just its effects. A DEA scheduling decision is still pending before Orzeyful reaches pharmacies, but clinicians call it the biggest shift in narcolepsy treatment in decades.
Read more →FDA approves first drug to treat the full range of narcolepsy symptoms
On August 5, 2026, the FDA approved Orzeyful (oveporexton), the first medicine designed to treat narcolepsy type 1 as a single, unified disorder rather than a collection of separate symptoms. Developed by Takeda, the twice-daily oral tablet is also the first approved drug that works by directly restoring orexin signaling, the brain chemical whose loss causes the disease, rather than masking symptoms with stimulants or sedatives. Approval rested on two randomized, double-blind, placebo-controlled trials enrolling 273 adults; patients on Orzeyful showed significantly longer ability to stay awake during the day and markedly fewer cataplexy episodes, with incidence-rate ratios of 0.34 to 0.38 versus placebo. Patients also reported improvement across the disorder's full symptom range, including sleep paralysis, hallucinations, and disrupted nighttime sleep. The drug received Breakthrough Therapy Designation and Priority Review earlier in 2026, reflecting the urgency researchers felt for a therapy addressing the disease's root cause rather than just its effects. A DEA scheduling decision is still pending before Orzeyful reaches pharmacies, but clinicians call it the biggest shift in narcolepsy treatment in decades.
Chemists break a decades-old rule governing electron transfer
Chemists at the University of Wisconsin-Madison, working with colleagues at Colorado State University and the University of Colorado Boulder, published a new catalytic strategy in Nature that broke a long-standing rule of electron-transfer chemistry, with the finding drawing wide science-press coverage on August 7, 2026. Traditionally, when two molecules compete for an electron in a reaction, physics dictates the electron goes to whichever molecule is easiest to reduce, limiting which reactions chemists can engineer. Led by UW-Madison professor Zachary Wickens, the team designed a catalyst that instead ejects an electron directly into the surrounding solvent, creating what Wickens described as "the strongest reductant and the most aggressive source of electrons you could possibly have." Once free in solution, that electron attaches to the first molecule it encounters, even one that would not normally be the preferred recipient, unlocking coupling reactions previously out of reach. Rather than a single new technique, the researchers say it offers a general new principle for designing oxidation-reduction reactions across organic chemistry. The advance could accelerate synthesis of new pharmaceuticals, agrochemicals, and materials by giving chemists a more reliable way to steer electrons toward otherwise inaccessible reaction pathways.
Read more →Chemists break a decades-old rule governing electron transfer
Chemists at the University of Wisconsin-Madison, working with colleagues at Colorado State University and the University of Colorado Boulder, published a new catalytic strategy in Nature that broke a long-standing rule of electron-transfer chemistry, with the finding drawing wide science-press coverage on August 7, 2026. Traditionally, when two molecules compete for an electron in a reaction, physics dictates the electron goes to whichever molecule is easiest to reduce, limiting which reactions chemists can engineer. Led by UW-Madison professor Zachary Wickens, the team designed a catalyst that instead ejects an electron directly into the surrounding solvent, creating what Wickens described as "the strongest reductant and the most aggressive source of electrons you could possibly have." Once free in solution, that electron attaches to the first molecule it encounters, even one that would not normally be the preferred recipient, unlocking coupling reactions previously out of reach. Rather than a single new technique, the researchers say it offers a general new principle for designing oxidation-reduction reactions across organic chemistry. The advance could accelerate synthesis of new pharmaceuticals, agrochemicals, and materials by giving chemists a more reliable way to steer electrons toward otherwise inaccessible reaction pathways.
New electrochemical technology turns seawater CO2 into permanent mineral storage
A research team led by professor Dong-Yeun Koh at Korea's KAIST, working with professor T. Alan Hatton's group at MIT, unveiled an electrochemical technology in early August 2026 that converts carbon dioxide dissolved in seawater into calcium carbonate, a stable mineral that locks the carbon away essentially permanently. Because removing dissolved carbon from seawater lets the ocean absorb more CO2 from the atmosphere, the method, called electrochemical dissolved ocean carbon removal (e-DOC), uses the ocean itself as a carbon sink without the leak-back risk that has plagued earlier direct-ocean-capture approaches. In tests using real seawater from Jeju Island, South Korea, the system ran stably for more than 120 hours, removing 80 to 90 percent of dissolved inorganic carbon while cutting electricity consumption by up to 54 percent compared with existing marine carbon-removal technologies. The research, published in the journal Advanced Energy Materials, was widely reported starting August 4, 2026. Because the process also produces hydrogen as a byproduct, the team says it could eventually help offset the energy costs of running carbon-removal plants at scale. Researchers say the efficiency and durability gains bring commercial-scale marine carbon removal significantly closer to reality.
Read more →New electrochemical technology turns seawater CO2 into permanent mineral storage
A research team led by professor Dong-Yeun Koh at Korea's KAIST, working with professor T. Alan Hatton's group at MIT, unveiled an electrochemical technology in early August 2026 that converts carbon dioxide dissolved in seawater into calcium carbonate, a stable mineral that locks the carbon away essentially permanently. Because removing dissolved carbon from seawater lets the ocean absorb more CO2 from the atmosphere, the method, called electrochemical dissolved ocean carbon removal (e-DOC), uses the ocean itself as a carbon sink without the leak-back risk that has plagued earlier direct-ocean-capture approaches. In tests using real seawater from Jeju Island, South Korea, the system ran stably for more than 120 hours, removing 80 to 90 percent of dissolved inorganic carbon while cutting electricity consumption by up to 54 percent compared with existing marine carbon-removal technologies. The research, published in the journal Advanced Energy Materials, was widely reported starting August 4, 2026. Because the process also produces hydrogen as a byproduct, the team says it could eventually help offset the energy costs of running carbon-removal plants at scale. Researchers say the efficiency and durability gains bring commercial-scale marine carbon removal significantly closer to reality.
White-tailed eagles return to Exmoor after a 200-year absence
On August 4, 2026, Forestry England and the Roy Dennis Wildlife Foundation released six young white-tailed eagles into Exmoor National Park, the first time the UK's largest bird of prey has been reintroduced there after vanishing from English skies more than 200 years ago due to persecution. The birds, taken as chicks from wild nests in Scotland under a NatureScot licence, mark the start of a three-year release phase within a wider reintroduction project that began on the Isle of Wight in 2019 and has so far released 45 eagles into southern England, several of which are now breeding; the first wild white-tailed eagle chick born in southern England since 1780 hatched in 2023. Up to 20 more young eagles are expected to be released at Exmoor over the next three years as the project works to expand the species' breeding range into south-west England. White-tailed eagles, with wingspans reaching up to 2.4 meters, were once widespread across Britain before habitat loss and shooting drove them to extinction in England by the early 19th century. Conservationists say establishing a second release site at Exmoor should help build a more resilient, geographically distributed population less vulnerable to localized threats, while Forestry England says it is working with local farmers to address concerns through monitoring and community engagement.
Read more →White-tailed eagles return to Exmoor after a 200-year absence
On August 4, 2026, Forestry England and the Roy Dennis Wildlife Foundation released six young white-tailed eagles into Exmoor National Park, the first time the UK's largest bird of prey has been reintroduced there after vanishing from English skies more than 200 years ago due to persecution. The birds, taken as chicks from wild nests in Scotland under a NatureScot licence, mark the start of a three-year release phase within a wider reintroduction project that began on the Isle of Wight in 2019 and has so far released 45 eagles into southern England, several of which are now breeding; the first wild white-tailed eagle chick born in southern England since 1780 hatched in 2023. Up to 20 more young eagles are expected to be released at Exmoor over the next three years as the project works to expand the species' breeding range into south-west England. White-tailed eagles, with wingspans reaching up to 2.4 meters, were once widespread across Britain before habitat loss and shooting drove them to extinction in England by the early 19th century. Conservationists say establishing a second release site at Exmoor should help build a more resilient, geographically distributed population less vulnerable to localized threats, while Forestry England says it is working with local farmers to address concerns through monitoring and community engagement.